On December 15th, Shanghai Pharmaceutical Holdings and Sanofi China announced the official signing of a strategic cooperation agreement. Both sides will engage in extensive cooperation across all channels and nationwide in key disease areas, including but not limited to cardiovascular diseases, central nervous system diseases, tumors, etc., focusing on multiple high-quality Sanofi products. This cooperation is a comprehensive upgrade of the long-term cooperation between Shanghai Pharmaceutical Holdings and Sanofi China. Through this win-win cooperation and business model, both parties will enable Sanofi's high-quality products to benefit more Chinese people and contribute to the sustainable development of China's local medical and health ecosystem.
Sanofi Greater China President Shi Wang stated: Shangyao Holdings is a leading pharmaceutical operating enterprise in China. We believe that by combining the core advantages of the two companies, we can bring high-quality drugs to more Chinese patients. Establishing a pharmaceutical innovation business model with local partners is an important part of Sanofi's China innovation development strategy. We will accelerate the speed of innovation research and development, expand the depth and breadth of innovation cooperation, enhance the height of innovation strategy, achieve innovative product pipelines and innovative business models "Two pronged approach, allowing more innovative, high-quality, and accessible original drugs and vaccines to benefit the Chinese people, and making continuous contributions to the Healthy China 2030 strategy."
Li Yongzhong, Executive Director and CEO of Shanghai Pharmaceuticals, stated: This is one of the largest, widest, and deepest strategic collaborations between the pharmaceutical industry and commerce in recent years. Currently, the fundamental conditions of China's medical system are undergoing significant changes, and there is an urgent need for new market models to achieve a balance and cooperation of "efficiency+innovation" and better serve the Healthy China strategy. This industrial chain cooperation has achieved a perfect balance between the commercial efficiency of local circulation enterprises and the innovation advantages of multinational pharmaceutical enterprises Cooperate to build a new ecosystem, promote the cross integration of industrial chain innovation chain, and more efficiently push more valuable drugs to the market and benefit the people. We believe that we have the ability to advance this new model of strategic cooperation to a higher level, and we also believe that the path created by this model will be unstoppable Through strong partnerships with partners such as Sanofi China, Shanghai Pharmaceutical Holdings aims to continuously strengthen the national omnichannel integrated marketing service system and is committed to building the top brand in China's pharmaceutical commercial marketing.